An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of ...

2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis 11-13 This positive opinion from the ...

and prurigo nodularis (firm bumps). Studies show people of color in the United States are more likely to develop atopic dermatitis and experience more severe symptoms compared to white people.

If you have a darker skin tone, you might see small, hardened, very itchy bumps, known as prurigo nodularis, on areas of your skin affected by atopic dermatitis. You may also be likely to get ...

Nemolizumab “is also the first and only biologic approved for atopic dermatitis and prurigo nodularis with 4-week dosing intervals from the start of treatment,” according to the statement.

7,8 “These late-breaking data further highlight the potential of nemolizumab as an effective, long-term therapeutic option for patients with atopic dermatitis and prurigo nodularis seeking relief from ...

Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis, with low adverse event rates in long-term use. The cream reduces the need for other topical treatments and biologics in ...

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis and prurigo nodularis in patients with moderate-to-severe cases of the skin ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The UK regulator has specifically ...

showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis 1-3 There is a need for new treatment options for atopic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.